163 related articles for article (PubMed ID: 16824042)
1. Deoxyribonuclease I footprinting reveals different DNA binding modes of bifunctional platinum complexes.
Chválová K; Kaspárková J; Farrell N; Brabec V
FEBS J; 2006 Aug; 273(15):3467-78. PubMed ID: 16824042
[TBL] [Abstract][Full Text] [Related]
2. DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent.
Brabec V; Kaspárková J; Vrána O; Nováková O; Cox JW; Qu Y; Farrell N
Biochemistry; 1999 May; 38(21):6781-90. PubMed ID: 10346899
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of the membrane interaction of polynuclear platinum anticancer agents. Implications for cellular uptake.
Liu Q; Qu Y; Van Antwerpen R; Farrell N
Biochemistry; 2006 Apr; 45(13):4248-56. PubMed ID: 16566599
[TBL] [Abstract][Full Text] [Related]
4. Cellular pharmacology of polynuclear platinum anti-cancer agents.
Roberts JD; Peroutka J; Farrell N
J Inorg Biochem; 1999 Oct; 77(1-2):51-7. PubMed ID: 10626354
[TBL] [Abstract][Full Text] [Related]
5. Translesion DNA synthesis across double-base lesions derived from cross-links of an antitumor trinuclear platinum compound: primer extension, conformational and thermodynamic studies.
Novakova O; Farrell NP; Brabec V
Metallomics; 2018 Jan; 10(1):132-144. PubMed ID: 29242879
[TBL] [Abstract][Full Text] [Related]
6. Studies on synthesis, activity and binding with DNA of a new trinuclear platinum compound [{trans-PtCl(NH3)2}2{trans-Pt(thiazole)2}{H2N(CH2)(6NH2}2]Cl3(NO3).
Al-Shuneigat J; Qing Y; Beale P; Fisher K; Huq F
Med Chem; 2011 Jan; 7(1):1-8. PubMed ID: 21235513
[TBL] [Abstract][Full Text] [Related]
7. Long range 1,4 and 1,6-interstrand cross-links formed by a trinuclear platinum complex. Minor groove preassociation affects kinetics and mechanism of cross-link formation as well as adduct structure.
Hegmans A; Berners-Price SJ; Davies MS; Thomas DS; Humphreys AS; Farrell N
J Am Chem Soc; 2004 Feb; 126(7):2166-80. PubMed ID: 14971952
[TBL] [Abstract][Full Text] [Related]
8. Chemical reactivity and DNA sequence specificity of formally monofunctional and bifunctional bis(platinum) complexes.
Wu PK; Qu Y; Van Houten B; Farrell N
J Inorg Biochem; 1994 May; 54(3):207-20. PubMed ID: 8027742
[TBL] [Abstract][Full Text] [Related]
9. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex.
Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V
Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702
[TBL] [Abstract][Full Text] [Related]
10. DNase I footprinting of cis- or trans-diamminedichloroplatinum(II)-modified DNA.
Schwartz A; Leng M
J Mol Biol; 1994 Mar; 236(4):969-74. PubMed ID: 8120904
[TBL] [Abstract][Full Text] [Related]
11. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
Kasparkova J; Novakova O; Farrell N; Brabec V
Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292
[TBL] [Abstract][Full Text] [Related]
12. Sequence-dependent conformational changes in DNA induced by polynuclear platinum complexes.
McGregor TD; Balcarová Z; Qu Y; Tran MC; Zaludová R; Brabec V; Farrell N
J Inorg Biochem; 1999 Oct; 77(1-2):43-6. PubMed ID: 10626352
[TBL] [Abstract][Full Text] [Related]
13. Competitive formation of DNA linkage isomers by a trinuclear platinum complex and the influence of pre-association.
Moniodis JJ; Thomas DS; Davies MS; Berners-Price SJ; Farrell NP
Dalton Trans; 2015 Feb; 44(8):3583-3593. PubMed ID: 25407024
[TBL] [Abstract][Full Text] [Related]
14. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
[TBL] [Abstract][Full Text] [Related]
15. A comparison of DNA binding profiles of dinuclear platinum compounds with polyamine linkers and the trinuclear platinum phase II clinical agent BBR3464.
McGregor TD; Hegmans A; Kaspárková J; Neplechová K; Nováková O; Penazová H; Vrána O; Brabec V; Farrell N
J Biol Inorg Chem; 2002 Apr; 7(4-5):397-404. PubMed ID: 11941497
[TBL] [Abstract][Full Text] [Related]
16. DNA adducts of antitumor trans-[PtCl2 (E-imino ether)2].
Brabec V; Vrána O; Nováková O; Kleinwächter V; Intini FP; Coluccia M; Natile G
Nucleic Acids Res; 1996 Jan; 24(2):336-41. PubMed ID: 8628659
[TBL] [Abstract][Full Text] [Related]
17. Consequences of nucleic acid conformation on the binding of a trinuclear platinum drug.
Kloster MB; Hannis JC; Muddiman DC; Farrell N
Biochemistry; 1999 Nov; 38(45):14731-7. PubMed ID: 10555954
[TBL] [Abstract][Full Text] [Related]
18. Interaction between cisplatin-modified DNA and the HMG boxes of HMG 1: DNase I footprinting and circular dichroism.
Locker D; Decoville M; Maurizot JC; Bianchi ME; Leng M
J Mol Biol; 1995 Feb; 246(2):243-7. PubMed ID: 7869375
[TBL] [Abstract][Full Text] [Related]
19. Bending studies of DNA site-specifically modified by cisplatin, trans-diamminedichloroplatinum(II) and cis-[Pt(NH3)2(N3-cytosine)Cl]+.
Bellon SF; Lippard SJ
Biophys Chem; 1990 Apr; 35(2-3):179-88. PubMed ID: 2397272
[TBL] [Abstract][Full Text] [Related]
20. Binding of polybenzamides to DNA: studies by DNase I and chlorambucil interference footprinting and comparison with Hoechst 33258.
Turner PR; Ferguson LR; Denny WA
Anticancer Drug Des; 1998 Dec; 13(8):941-54. PubMed ID: 10335268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
